Inquest reopens scrutiny of breast cancer surgery in Ian Paterson’s patients

The death of Gillian Hudson has brought renewed attention to the long shadow left by breast cancer surgery carried out by jailed surgeon Ian Paterson. Her inquest heard that she was recalled to hospital years after her mastectomy because of concerns that some of Paterson’s patients had undergone cleavage-sparing procedures, an unregulated operation that could leave breast tissue behind.

Residual breast tissue after mastectomy can create a dangerous false sense of security. If tissue is left in place, malignant cells may persist, recur locally, or seed later disease, especially in a patient whose original cancer biology was already concerning.

Hudson first noticed a lump in her right breast in 2003 and was referred by her GP to Solihull Hospital. A doctor there recorded the lump, judged it not suspicious, and arranged a mammogram for a month later rather than fast-tracking the assessment the same day. She later came under Paterson’s care, and the mammogram suggested an early form of breast cancer. Paterson then said further examination showed something “considerably more aggressive or worrying than we thought,” before performing a mastectomy.

Questions over the operation she received

The central medical concern in this case is not simply that Hudson had breast cancer, but whether the surgery achieved the oncologic goal of complete excision. In 2011, the NHS recalled a number of Paterson’s patients after concerns emerged about cleavage-sparing mastectomies, a technique he carried out without regulation and one that could leave tissue in place in the chest wall or breast skin envelope.

Doctors were unable to determine from later review whether Hudson had undergone that exact procedure because reconstruction obscured the operative anatomy. Her own statement to the General Medical Council described the post-operative appearance as though the breast skin had been “rolled or folded,” and not flat as she had expected. Paterson countered that the shape may have reflected inflammation and said several other doctors had not raised concerns about residual tissue.

This type of dispute matters in oncology because surgical completeness influences follow-up decisions, recurrence risk assessment, and the interpretation of later symptoms. A reconstructed breast can make clinical inspection more difficult, and when the original operation is questioned years later, imaging and examination may no longer provide a definitive answer.

Recurrence years later and the burden of uncertainty

Hudson was diagnosed with breast cancer again in 2016, then developed liver and lung metastases before her death in 2022 at the age of 63. Paterson has said her death had nothing to do with the surgery he performed, calling that idea “absolute nonsense.” The inquest has not reached that question, but the sequence of events is stark: a woman treated for breast cancer, recalled years later amid concerns about the quality of her operation, then diagnosed again before dying with disseminated disease.

Her case illustrates how uncertainty around surgery can linger far beyond the operating theatre. If adequate tissue clearance was not achieved initially, the patient may carry an elevated risk of recurrence that is difficult to reconstruct retrospectively. If the later cancer represented a new primary tumour, the question shifts, but the clinical and medicolegal consequences remain serious because the first operation still shaped the post-treatment surveillance pathway.

Hudson’s son Dan told the inquest that family was her greatest joy. He described a woman who worked for 23 years at King Edwards School in Edgbaston, taught religion and philosophy, went to the gym seven days a week, and still found time for practical jokes. Those details do not alter the pathology, but they do frame what was lost: a life that continued for years after the first diagnosis, then narrowed under the weight of metastatic disease.

What the ongoing inquests mean for breast cancer care

Paterson was jailed in 2017 and given a 20-year sentence after being convicted of wounding patients through botched and unnecessary operations. He is due for release at the halfway point of that sentence in May next year, while inquests into the deaths of former patients continue.

There are now 74 inquests open into the deaths of his former patients, a figure that reflects the scale of the harm now being examined. In one case, the death of 83-year-old Joan Green is already being investigated by West Midlands Police after being referred by the coroner, marking the first police investigation into the death of one of Paterson’s patients.

The clinical lessons here are uncomfortable but concrete. Breast cancer surgery is only as safe as the standards that govern it, and when those standards are bypassed, reconstruction, surveillance, and later review all become harder. A mastectomy that leaves behind tissue can complicate every subsequent stage of care, from the interpretation of the chest wall to the assessment of recurrence years later.

Hudson’s inquest will continue later this month, when other medical experts are expected to address her care. Until then, the unresolved question is not whether she lived with breast cancer, but whether the operation intended to remove it left too much behind for anyone to know with certainty.


Reporting by Dr. Revathy Mohan V.R., MBBS for Medicine World Foundation, with additional data provided by BBC News — Dentistry.